Pfizer Inc. and partner BioNTech SE lifted global spirits when interim results from Phase III trials of their m-RNA vaccine candidate showed over 90% efficacy in preventing COVID-19 infection at seven days after the second dose. Though the news was welcomed in India as well, commercial gains for domestic companies are not on the horizon soon. (Also see "Pfizer And BioNTech Claim COVID-19 Vaccine Success" - Scrip, 9 November, 2020.)
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?